Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 15/20 | 0.60 |
| ▸ | CNR2 | P34972 | 2/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30469272 | 0.78 | CNR1 (0.84) | CNR1NPC1RAB9AMAPTTP53 | |
| SCHEMBL4117269 | 0.78 | CNR1 (0.84) | CNR1NPC1RAB9AMAPTTP53 | |
| SCHEMBL30469305 | 0.77 | CNR1 (0.95) | CNR1CNR2NPC1RAB9AFAAH | |
| SCHEMBL20557639 | 0.77 | CNR1 (0.95) | CNR1CNR2NPC1RAB9AFAAH | |
| SCHEMBL4106738 | 0.77 | NPC1 (0.64) | CNR1EPHX2NPC1RAB9AMAPT | |
| SCHEMBL20557908 | 0.77 | CNR1 (0.55) | CNR1EPHX2NPC1RAB9AMAPT | |
| SCHEMBL30469239 | 0.77 | CNR1 (0.55) | CNR1EPHX2NPC1RAB9AMAPT | |
| SCHEMBL20557713 | 0.76 | CNR1 (0.92) | CNR1CNR2NPC1RAB9AFAAH | |
| SCHEMBL30469227 | 0.76 | CNR1 (0.92) | CNR1CNR2NPC1RAB9AFAAH | |
| SCHEMBL20557676 | 0.76 | CNR1 (0.92) | CNR1CNR2NPC1RAB9AFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084781-B2 | Diarylureas as CB1 allosteric modulators | RESEARCH TRIANGLE INSTITUTE (US) | 2021-08-10 | — | — | US | disclosed |
| US-20200062699-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084781-B2 | Diarylureas as CB1 allosteric modulators | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885EPHX2 1805/4885 |
| US-20200062699-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885EPHX2 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.